Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)

被引：0
|
作者：
Gilbert, Jill
Schell, Michael J.
Zhao, Xiuhua
Murphy, Barbara A.
Tanvetyanon, Tawee
Hayes, David N.
Haigentz, Missak
Saba, Nabil F.
Nieva, Jorge J.
Perez, Jimena
Bishop, Justin A.
Chung, Christine H.
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA
[4] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA
[5] Montefiore Med Ctr, Dept Oncol, Bronx, NY 10467 USA
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] Billings Clin Canc Ctr, Billings, MT USA
[8] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6047
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Palliative chemotherapy (CT) with or without cetuximab (CTX) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An Indian retrospective analysis
    Bahl, A.
    Choudhary, P.
    Bhatia, K.
    Singhla, S.
    Shrivastava, G.
    Bal, J.
    Anand, A. K.
    Chaturvedi, H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Retrospective analysis of the use of cetuximab (CTX) and paclitaxel (PTX) combination in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Soria Rivas, Ainara
    Rodriguez Garrote, Mercedes
    Olmedo Garcia, Maria Eugenia
    Lopez, Maria
    Garrido Lopez, Pilar
    Carrato, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
    Wakasugi, T.
    Enokida, T.
    Nakanome, A.
    Yamazaki, T.
    Okano, S.
    Tahara, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
  • [4] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    [J]. ORAL ONCOLOGY, 2023, 147
  • [5] Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Mehra, Ranee
    Egloff, Ann Marie
    Li, Shuli
    Yang, Donghua
    Wang, Lin
    Zhu, Fang
    Forastiere, Arlene A.
    Burtness, Barbara
    Argiris, Athanassios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara
    Tanvetyanon, Tawee
    Leon, Marino E.
    Hayes, D. Neil
    Haigentz, Missak, Jr.
    Saba, Nabil
    Nieva, Jorge
    Bishop, Justin
    Sidransky, David
    Ravi, Rajani
    Bedi, Atul
    Chung, Christine H.
    [J]. ORAL ONCOLOGY, 2015, 51 (04) : 376 - 382
  • [7] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [8] Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Fekih, M.
    Ferrand, F. R.
    Saada, E.
    Hamdan, D.
    Desmaris, R.
    Schilf, A.
    Guigay, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S568 - S569
  • [9] Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Fayette, J.
    Lefebvre, G.
    Posner, M. R.
    Bauman, J.
    Salas, S.
    Even, C.
    Saada-Bouzid, E.
    Seiwert, T.
    Colevas, D.
    Calmels, F.
    Zerbib, R.
    Chammard, A. Boyer
    Cohen, R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 374 - 374
  • [10] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
12345